| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
Correspondence |
Salford Community Health Care NHS Trust, Meadowbrook, Department of Psychological Medicine, Stott Lane, Salford M6 8HG, UK
In January 2001 the National Institute for Clinical Excellence (NICE) published Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. The guidance indicates that the drugs should be made available within the National Health Service to people with mild to moderate Alzheimer's disease whose minimental state examination (MMSE) score is above 12 points. The Institute's guidance does not mention the use of anti-dementia drugs in people with learning disabilities and Alzheimer's disease. Studies have shown that the prevalence of Alzheimer's disease in those with learning disabilities is higher than in the normal population (Patel et al, 1993). This is likely to increase in the future because of the rising life expectancy of people with learning disabilities (Zigman et al, 1997). In Down's syndrome, approximately 40% develop dementia of Alzheimer type by the age of 60 (Holland et al, 1998).
It is known that clinical evidence for the effectiveness of various psychiatric treatments in the learning disability population is scanty and specialists rely on evidence from the normal population. In this situation, a specialist in the psychiatry of learning disability might consider following the NICE guidance in treating dementia in the people under his or her care. However, there is a major problem, as NICE guidance suggests that treatment should be monitored by MMSE score but the MMSE cannot be used reliably in people with learning disabilities (Deb & Braganza, 1999). This means that NICE guidance on the use of antidementia drugs is not applicable to people with learning disabilities. This is likely to discourage specialists from prescribing treatment for some patients with a learning disability and Alzheimer's disease who may benefit from it in future. In its guidance, NICE mentioned limitations on the use of the MMSE in people whose Alzheimer's disease is complicated by dysphasia and whose first language is not English, but failed to identify that the MMSE is not standardised for people with learning disabilities who make up 2% of our population. The fact that this group of people, with a high prevalence of dementia, was completely ignored within the guidance is quite worrying. We appreciate that the guidance from NICE is not prescriptive and does not replace individual judgement; however, complete omission of learning disability could potentially exclude people from receiving beneficial treatment.
REFERENCES
Deb, S. & Braganza, J. (1999) Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome. Journal of Intellectual Disability Research, 43, 400-408.
Holland, A. J., Hon, J., Huppert, F. A., et al
(1998) Population-based study of prevalence and presentation
of dementia in adults with Down's syndrome. British Journal of
Psychiatry, 172,
493-498.
National Institute for Clinical Excellence (2001) Guidance for the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. London: NICE.
Patel, P., Goldberg, D. & Moss, T. (1993)
Psychiatric morbidity in older people with moderate and severe learning
disability. II: The prevalence study. British Journal of
Psychiatry, 163,
481-491.
Zigman, W., Schupf, N., Haveman, M., et al (1997) The epidemiology of Alzheimer's disorder in intellectual disability: results and recommendations from an international conference. Journal of Intellectual Disability Research, 41, 76-80.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
